NIR-I-to-NIR-II fluorescent nanomaterials for biomedical imaging and cancer therapy.
NIR-I-to-NIR-II fluorescent nanomaterials for biomedical imaging and cancer therapy.
复制标题
DOI：
10.1039/c7tb02573d
复制
发表时间：
2018-01
期刊：
影响因子：
--
通讯作者：
Jingya Zhao;Dian Zhong;Shaobing Zhou
中科院分区：
文献类型：
--
作者：
Jingya Zhao;Dian Zhong;Shaobing Zhou
近红外(NIR)荧光成像是一种在生物医学研究和临床应用中都具有吸引力的成像方式，由于近红外光子在组织中的深度穿透，提供了高分辨率的成像。为了在增加组织深度的情况下进一步提高图像对比度，近年来，近红外成像技术的发展受到了极大的关注，它可以显著减少光子吸收、散射和组织自身荧光对700-950 nm NIR-I窗口激发和1000-1700 nm NIR-II窗口发射的干扰。在这篇综述中，我们重点介绍了最近发展起来的NIR-I-to-NIR-II荧光纳米材料，包括硫化物银量子点、单壁碳纳米管和聚合物纳米粒子。通过与传统荧光团的比较，讨论了这些纳米材料作为荧光标记在深部组织成像中的优势，并综述了利用这些纳米材料实现近红外荧光成像的方法，包括纳米材料的仪器、数据分析和表面生物功能化。最后，我们讨论了NIR-I-to-NIR-II荧光纳米材料在生物医学成像领域的最新应用，重点是如何利用它们来实现癌症诊断和治疗的同步。
Near-infrared (NIR) fluorescence imaging, which affords high imaging resolution owing to deep tissue penetration of NIR photons, is an attractive imaging modality for both biomedical research and clinical applications. To further improve the image contrast at increased tissue depth, recently much attention has been focused on the development of NIR-I-to-NIR-II fluorescence imaging, which can remarkably reduce the interference from photon absorption, scattering and tissue autofluorescence with excitation in the 700-950 nm NIR-I window and emission in the 1000-1700 nm NIR-II window. In this review, we highlight recently developed NIR-I-to-NIR-II fluorescent nanomaterials, including silver chalcogenide quantum dots, single-walled carbon nanotubes and polymer nanoparticles. We discuss the advantages of these nanomaterials as fluorescent tags in deep tissue imaging by comparing them with conventional fluorophores, and then survey the implementation of NIR fluorescence imaging with these nanomaterials, including instrumentation, data analysis and surface biofunctionalization of the nanomaterials. Finally, we discuss recent applications of NIR-I-to-NIR-II fluorescent nanomaterials in the biomedical imaging field, with an emphasis on how to use them to achieve simultaneous cancer diagnosis and therapy.